Table 1

Baseline characteristics. All patients and patients divided in two subgroups: (1) treatment included the better seeing-eye (BSE) defined by best corrected visual acuity (BCVA) (the subgroup also contained patients receiving bilateral treatment) and (2) patients for which treatment only included the worse-seeing eye (WSE)

ParametersAll patients (n=197)Patients with BSE treated (n=52)Patients with WSE treated (n=145)BSE vs WSE treated (P value)
BCVA treated eye logMAR Fractional0.59±0.51
20/78
0.39±0.31
20/49
0.68±0.57
20/96
0.010*
BCVA best eye logMAR
Fractional
0.19±0.26
20/31
0.39±0.31
20/49
0.11±0.19
20/26
<0.001**
NEI-VFQ2579.53±14.5271.25±16.5082.48±12.56<0.001**
PASS3.30±0.803.60±0.663.20±0.820.002**
EQ-5D0.74±0.280.68±0.320.76±0.260.085
  • Bold denotes significant change from baseline: **p<0.001 and *p<0.05. Mean value (SD).

  • EQ-5D, EuroQol Group Questionnaire; NEI-VFQ-25, National Eye Institute Visual-Functioning-Questionnaire-25.